Ophthalmic trauma, artificial intelligence and disparities mark key themes of AAO 2021
The American Academy of Ophthalmology conference is scheduled to take place in person and online from November 12-15, 2021.
In a hybrid face-to-face and online meeting, the American Academy of Ophthalmology (AAO) will host its 2021 annual conference from Friday, November 12 through Monday, November 15 in New Orleans, Louisiana.
All in-person meeting attendees are required to show proof of COVID-19 vaccination and must wear masks throughout the conference.
On-demand and live sessions are expected to address trends in the field, including improving eye care disparities in the United States, the impact of COVID-19 on the practice of ophthalmology, and the implications of eye care. technological advances in ophthalmology.
New developments on surgical innovations for ophthalmology and treatments for diseases such as glaucoma, thyroid eye disease (TED) and optic nerve diseases will also be presented.
Several sessions focus on ophthalmic trauma, reflecting a change in the field in recent years, explained James Auran, MD, professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, in an interview. with The American Journal of Managed Care® (AJMC®).
“There was huge interest [in ophthalmic trauma], and a lot of people have dedicated their lives to it, but they haven’t had traction until recently, ”Auran said. “I guess it just hit a tipping point about 2-3 years ago and here we are.”
The on-demand session in which Auran will participate, “Open Globe Trauma: Surgical Management for the On-Call Ophthalmologist”, is scheduled for Sunday, November 14, 2021 from 3:45 pm to 5:00 pm CDT.
Additional speakers at AAO 2021 will discuss the current state of pediatric ophthalmology, developments in astigmatism, cataracts and cosmetic procedures, as well as physician burnout.
As teprotumumab (Tepezza) is the first and only drug approved for the treatment of PDD, several summaries and sessions will focus on actual data on adherence and adverse reactions reported since its approval in 2020. In one session, Anne Barmettler, MD, director of ophthalmic plastic and reconstructive surgery and associate professor of ophthalmology and visual sciences at Montefiore Medical Center, will provide updates on the drug. His presentation, “Teprotumumab: One Year After FDA Approval – What We Know and What We Don’t Know,” will take place on Sunday, November 14 at 12:12 pm CDT.
Experts will also discuss the advent and use of artificial intelligence in ophthalmology at AAO 2021, with presentations highlighting how it can be integrated into practice and used for screening purposes.